ArticleInternational journal of women's health2010
Treating dyspareunia caused by vaginal atrophy: a review of treatment options using vaginal estrogen therapy.
Article in International journal of women's health, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03782480 (A Placebo-controlled Study Examining the Morphological/Biochemical Effects of Intrarosa on the Vulvar Vestibule and Vagina in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy), which is not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Placebo-controlled Study Examining the Morphological/Biochemical Effects of Intrarosa on the Vulvar Vestibule and Vagina in Women With Genitourinary Syndrome of Menopause/Vulvovaginal Atrophy
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Hormonal Treatments and Vaginal Moisturizers for Genitourinary Syndrome of Menopause : A Systematic Review.Annals of internal medicine · 2024Pooled it
- Effects of ospemifene on genitourinary health assessed by prospective vulvar-vestibular photography and vaginal/vulvar health indices.Menopause (New York, N.Y.) · 2019Trial
- Autologous Platelet-Released Growth Factor and Sexual Dysfunction Amendment: A Pilot Clinical Trial of Successful Improvement Sexual Dysfunction after Pelvic IrradiationAsian Pacific journal of cancer prevention : APJCP · 2019Trial
- Endocrine disrupting chemicals and female sexual health: An emerging research priority.Environmental research · 2025Article
- Efficacy and Safety of Intravaginal Estrogen in the Treatment of Atrophic Vaginitis: A Systematic Review and Meta-Analysis.Journal of menopausal medicine · 2024Article
- Testosterone use and sexual function among transgender men and gender diverse people assigned female at birth.American journal of obstetrics and gynecology · 2023Article
- Fractional COJournal of clinical medicine · 2023Article
- Management of genitourinary syndrome of menopause in breast cancer survivors: An update.World journal of clinical oncology · 2022Review
- Treatment of genitourinary syndrome of menopause: the potential effects of intravaginal ultralow-concentration oestriol and intravaginal dehydroepiandrosterone on quality of life and sexual function.Przeglad menopauzalny = Menopause review · 2019Review
- Genital vibration for sexual function and enhancement: best practice recommendations for choosing and safely using a vibrator.Sexual and relationship therapy : journal of the British Association for Sexual and Relationship Therapy · 2018Article
- A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy.Therapeutic advances in medical oncology · 2017Review
- Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey.Climacteric : the journal of the International Menopause Society · 2016Article
- How to ask and what to do: a guide for clinical inquiry and intervention regarding female sexual health after cancer.Current opinion in supportive and palliative care · 2016Review
- Comparison of the Hyaluronic Acid Vaginal Cream and Conjugated Estrogen Used in Treatment of Vaginal Atrophy of Menopause Women: A Randomized Controlled Clinical Trial.International journal of community based nursing and midwifery · 2016Article
- Effects of ospemifene on the female reproductive and urinary tracts: translation from preclinical models into clinical evidence.Menopause (New York, N.Y.) · 2015Review
- Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue.Journal of personalized medicine · 2015Article
- Management of Vaginal Atrophy: Implications from the REVIVE Survey.Clinical medicine insights. Reproductive health · 2014Review
- Improved compliance and patient satisfaction with estradiol vaginal tablets in postmenopausal women previously treated with another local estrogen therapy.International journal of women's health · 2013Article
- Overcoming resistance and barriers to the use of local estrogen therapy for the treatment of vaginal atrophy.International journal of women's health · 2012Article
- Squill oil for decreasing dyspareunia and increasing sexual satisfaction in menopausal women: A triple-blind randomized controlled trial.Avicenna journal of phytomedicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vulvovaginal atrophy (VVA) and dryness are common symptoms of the decline in endogenous production of estrogen at menopause and often result in dyspareunia. Yet while 10% to 40% of women experience discomfort due to VVA, it is estimated that only 25% seek medical help. The main goals of treatment for vaginal atrophy are to improve symptoms and to restore vaginal and vulvar anatomic changes. Treatment choices for postmenopausal dyspareunia resulting from vulvovaginal atrophy will depend on the underlying etiology and might include individualized treatment. A number of forms of vaginal estrogen and manner of delivery are currently available to treat moderate to severe dyspareunia caused by VVA. They all have been shown to be effective and are often the preferred treatment due to the targeted efficacy for urogenital tissues while resulting in only minimal systemic absorption. Both healthcare professionals and patients often find it difficult to broach the subject of sexual problems associated with VVA. However, with minimal effort to initiate a conversation about these problems, healthcare providers can provide useful information to their postmenopausal patients in order to help them each choose the optimal treatment for their needs and symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.